Kenvue (KVUE) Projected to Post Quarterly Earnings on Thursday

Kenvue (NYSE:KVUE) is expected to announce its Q4 2025 results before the market opens on Thursday, February 5th. Analysts expect the company to announce earnings of $0.22 per share for the quarter. Kenvue has set its FY 2025 guidance at 1.000-1.050 EPS. Investors may visit the the company’s upcoming Q4 2025 earning results page for the latest details on the call scheduled for Friday, February 6, 2026 at 12:30 PM ET.

Kenvue (NYSE:KVUE) last released its earnings results on Monday, November 3rd. The company reported $0.28 earnings per share for the quarter, beating analysts’ consensus estimates of $0.27 by $0.01. The company had revenue of $3.76 billion during the quarter, compared to analyst estimates of $3.83 billion. Kenvue had a return on equity of 20.02% and a net margin of 9.55%.Kenvue’s revenue for the quarter was down 3.5% on a year-over-year basis. During the same quarter in the previous year, the company posted $0.28 EPS. On average, analysts expect Kenvue to post $1 EPS for the current fiscal year and $1 EPS for the next fiscal year.

Kenvue Trading Down 0.8%

Shares of KVUE stock opened at $17.36 on Thursday. The business has a 50-day moving average of $17.13 and a 200 day moving average of $18.08. The company has a debt-to-equity ratio of 0.66, a current ratio of 0.98 and a quick ratio of 0.69. Kenvue has a 1-year low of $14.02 and a 1-year high of $25.17. The stock has a market capitalization of $33.25 billion, a PE ratio of 23.14 and a beta of 0.60.

Kenvue Announces Dividend

The company also recently announced a dividend, which will be paid on Wednesday, February 25th. Stockholders of record on Wednesday, February 11th will be issued a $0.2075 dividend. The ex-dividend date is Wednesday, February 11th. Kenvue’s dividend payout ratio (DPR) is currently 110.67%.

Insider Buying and Selling

In related news, Director Jeffrey C. Smith acquired 3,200,000 shares of the stock in a transaction on Friday, December 12th. The stock was acquired at an average cost of $17.37 per share, for a total transaction of $55,584,000.00. Following the completion of the acquisition, the director directly owned 27,307,632 shares of the company’s stock, valued at approximately $474,333,567.84. This represents a 13.27% increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 0.17% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in the company. Arrowstreet Capital Limited Partnership purchased a new stake in Kenvue in the second quarter worth $6,528,000. Jump Financial LLC raised its holdings in Kenvue by 210.6% in the second quarter. Jump Financial LLC now owns 54,823 shares of the company’s stock worth $1,147,000 after purchasing an additional 37,170 shares in the last quarter. AXA S.A. lifted its position in Kenvue by 21.1% during the second quarter. AXA S.A. now owns 48,892 shares of the company’s stock valued at $1,023,000 after buying an additional 8,524 shares during the period. NewEdge Advisors LLC boosted its holdings in shares of Kenvue by 219.1% during the 2nd quarter. NewEdge Advisors LLC now owns 97,481 shares of the company’s stock valued at $2,040,000 after buying an additional 66,930 shares in the last quarter. Finally, The Manufacturers Life Insurance Company grew its position in shares of Kenvue by 0.6% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 1,873,705 shares of the company’s stock worth $39,217,000 after buying an additional 10,885 shares during the period. Institutional investors own 97.64% of the company’s stock.

Analyst Upgrades and Downgrades

Several research analysts recently commented on the stock. Edward Jones downgraded shares of Kenvue from a “strong-buy” rating to a “hold” rating in a research note on Monday, November 3rd. JPMorgan Chase & Co. dropped their target price on shares of Kenvue from $24.00 to $21.00 and set an “overweight” rating for the company in a report on Friday, October 10th. Jefferies Financial Group reduced their price target on Kenvue from $25.00 to $23.00 and set a “buy” rating on the stock in a report on Monday, October 27th. Zacks Research raised Kenvue from a “strong sell” rating to a “hold” rating in a research report on Wednesday, November 26th. Finally, Evercore ISI set a $18.00 price objective on Kenvue in a research report on Tuesday, October 28th. One analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and twelve have assigned a Hold rating to the company. According to MarketBeat.com, Kenvue currently has an average rating of “Hold” and an average price target of $20.23.

Kenvue Company Profile

Kenvue is a consumer health company that was established as a standalone, publicly traded business after separating from Johnson & Johnson. Listed on the New York Stock Exchange under the symbol KVUE, Kenvue focuses on the development, manufacture, marketing and distribution of consumer health and personal care products across a range of categories including skin and beauty care, baby care, oral care, wound care and over‑the‑counter medicines.

The company owns and markets a portfolio of widely recognized consumer brands, including names familiar to global shoppers across retail and pharmacy channels.